Investigation of brain iron levels in Chinese patients with Alzheimer’s disease
暂无分享,去创建一个
Kexue Deng | Chuanbin Huang | Jing Li | Yong Zhang | X. Lv | Qiqiang Tang | Chang Liu | Mengyue Ruan
[1] 2023 Alzheimer's disease facts and figures , 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[2] Ji-Rong Wen,et al. Altered brain iron depositions from aging to Parkinson's disease and Alzheimer's disease: A quantitative susceptibility mapping study , 2022, NeuroImage.
[3] F. Pasquier,et al. Quantitative susceptibility mapping demonstrates different patterns of iron overload in subtypes of early-onset Alzheimer’s disease , 2022, European Radiology.
[4] F. Gao,et al. A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[5] W. Moon,et al. Magnetic susceptibility in the deep gray matter may be modulated by apolipoprotein E4 and age with regional predilections: a quantitative susceptibility mapping study , 2022, Neuroradiology.
[6] Yige Wang,et al. Associations of cortical iron accumulation with cognition and cerebral atrophy in Alzheimer’s disease , 2022, Quantitative imaging in medicine and surgery.
[7] P. Paez,et al. H‐ferritin expression in astrocytes is necessary for proper oligodendrocyte development and myelination , 2021, Glia.
[8] Benjamin C. Tendler,et al. Phenotypic and genetic associations of quantitative magnetic susceptibility in UK Biobank brain imaging , 2021, bioRxiv.
[9] J. Weuve,et al. Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060) , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[10] B. Hyman,et al. APOE and Alzheimer’s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches. , 2021, The Lancet Neurology.
[11] Sungshin Kim,et al. Spatiotemporal dissociation of fMRI activity in the caudate nucleus underlies human de novo motor skill learning , 2020, Proceedings of the National Academy of Sciences.
[12] Christian Enzinger,et al. Cross-sectional and Longitudinal Assessment of Brain Iron Level in Alzheimer Disease Using 3-T MRI. , 2020, Radiology.
[13] R. Egli,et al. Effects of Alzheimer’s disease and formalin fixation on the different mineralised-iron forms in the human brain , 2020, Scientific Reports.
[14] O. Hansson,et al. Relationship between cortical iron and tau aggregation in Alzheimer’s disease , 2020, Brain : a journal of neurology.
[15] T. Südhof,et al. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk , 2019, The Journal of Neuroscience.
[16] P. Robert,et al. Alzheimer's disease: Estimating its prevalence rate in a French geographical unit using the National Alzheimer Data Bank and national health insurance information systems , 2019, PloS one.
[17] Chunlei Liu,et al. Imaging beta amyloid aggregation and iron accumulation in Alzheimer's disease using quantitative susceptibility mapping MRI , 2019, NeuroImage.
[18] J. Schneider,et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology , 2019, Molecular Psychiatry.
[19] P. Adlard,et al. Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration , 2018, Front. Mol. Neurosci..
[20] Peter C. M. van Zijl,et al. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age , 2018, NeuroImage.
[21] Lei Wang,et al. Increased Iron Deposition on Brain Quantitative Susceptibility Mapping Correlates with Decreased Cognitive Function in Alzheimer's Disease. , 2018, ACS chemical neuroscience.
[22] Qing X. Yang,et al. Dietary lipophilic iron alters amyloidogenesis and microglial morphology in Alzheimer's disease knock-in APP mice. , 2018, Metallomics : integrated biometal science.
[23] Ronald C. Petersen,et al. Practice guideline update summary: Mild cognitive impairment , 2018, Neurology.
[24] Joseph J. Gallagher,et al. Iron Biochemistry is Correlated with Amyloid Plaque Morphology in an Established Mouse Model of Alzheimer's Disease. , 2017, Cell chemical biology.
[25] Emily C. Collins,et al. Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer's disease , 2017, NeuroImage.
[26] T. Hirai,et al. Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care , 2017, Journal of magnetic resonance imaging : JMRI.
[27] A. Bush,et al. Evidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[28] Yi Wang,et al. Quantitative susceptibility mapping to evaluate the early stage of Alzheimer's disease☆ , 2017, NeuroImage: Clinical.
[29] Olivier Salvado,et al. Cerebral quantitative susceptibility mapping predicts amyloid-&bgr;-related cognitive decline , 2017, Brain : a journal of neurology.
[30] A. F. Gietl,et al. Colocalization of cerebral iron with Amyloid beta in Mild Cognitive Impairment , 2016, Scientific Reports.
[31] Josep Samitier,et al. Magnetite-Amyloid-β deteriorates activity and functional organization in an in vitro model for Alzheimer’s disease , 2015, Scientific Reports.
[32] Wei Li,et al. Susceptibility‐weighted imaging and quantitative susceptibility mapping in the brain , 2015, Journal of magnetic resonance imaging : JMRI.
[33] Wei Cao,et al. A method for estimating and removing streaking artifacts in quantitative susceptibility mapping , 2015, NeuroImage.
[34] Yi Wang,et al. Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker , 2014, Magnetic resonance in medicine.
[35] Christian Langkammer,et al. Differential developmental trajectories of magnetic susceptibility in human brain gray and white matter over the lifespan , 2014, Human brain mapping.
[36] Saifeng Liu,et al. Measuring iron in the brain using quantitative susceptibility mapping and X-ray fluorescence imaging , 2013, NeuroImage.
[37] Peng Lei,et al. A delicate balance: Iron metabolism and diseases of the brain , 2013, Front. Aging Neurosci..
[38] Ferdinand Schweser,et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.
[39] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[40] Bing Wu,et al. Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition , 2011, NeuroImage.
[41] Ferdinand Schweser,et al. Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: An approach to in vivo brain iron metabolism? , 2011, NeuroImage.
[42] Kyle L. Morris,et al. Iron Promotes the Toxicity of Amyloid β Peptide by Impeding Its Ordered Aggregation* , 2010, The Journal of Biological Chemistry.
[43] Wei Wang,et al. Quantitative MR phase-corrected imaging to investigate increased brain iron deposition of patients with Alzheimer disease. , 2009, Radiology.
[44] G. Perry,et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Connor,et al. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains , 1992, Journal of neuroscience research.
[46] D. McLachlan,et al. Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.
[47] B. Hallgren,et al. THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.
[48] Won-Jin Moon,et al. Patterns of Brain Iron Accumulation in Vascular Dementia and Alzheimer's Dementia Using Quantitative Susceptibility Mapping Imaging. , 2016, Journal of Alzheimer's disease : JAD.
[49] M. Ganguli,et al. Practice guideline update summary: Mild cognitive impairment Report of theGuidelineDevelopment, Dissemination, and Implementation Subcommittee of the American Academy ofNeurology , 2022 .